# Leah Ferguson

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/leah-ferguson
Canonical HTML page: https://getbiobrief.com/entity/leah-ferguson

## Recent coverage (1 stories)

### Vorasidenib’s $336K Annual Cost Slashed as PBS Validates IDH Inhibitor Market
2026-08-02 08:30:24 · Sentiment: Positive · Impact: 6/10 · Sources: 2

The PBS listing of Servier’s vorasidenib transforms a $28,000/month orphan drug into a mass-market treatment, commercializing the first IDH inhibitor for brain cancer in two decades. This regulatory win validates the IDH pathway and could ignite further investment in rare neuro-oncology pipelines, as Australia’s move signals payer willingness to cover high-cost precision therapies.
Full story: https://getbiobrief.com/story/vorasidenib-pbs-listing-idh-mutant-glioma

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.